LYMPHAGEN, INC.
Modulating lymphatic regeneration to improve human disease
Welcome. We’re Lymphagen, Inc., and we’re disrupting the industry with our groundbreaking solutions for lymphedema and other lymphatic diseases based on over a decade of NIH funded research. Our patented technology has already been recognized by market leaders. Curious to find out more? Browse through our website, and get in touch if you would like to request more information.
WHO WE ARE
Lymphagen, Inc. is developing cutting-edge technologies and services, for patients with limited treatment options. Rooted in research from co-inventors Alex Wong, MD (Rutgers) & Young-Kwon Hong (Harvard), and co-led by industry veteran Greg Park (former senior global executive, PTC Therapeutics, Inc.), we are an early stage biotechnology startup company that aims to modulate lymphangiogenesis after surgical injury as well as for a host of other important disease processes. Get in touch today to learn more.
OUR TECHNOLOGY
Smart solutions are at the core of all that we do at Lymphagen, Inc.. Our main goal is finding smart ways of using technology that will help build a better tomorrow for everyone, everywhere. Click below to learn more about the technology behind our Biotechnology Startup, or get in touch to set up a meeting with one of our representatives.
"Big results require big ambitions"
